Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Mg Pidolate

Phase 2Small molecule

BBaylor College of Medicine

Mg Pidolate is one of 2 small molecule programs targeting Hemoglobin SC Disease. It is currently in Phase 2.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemoglobin SC DiseaseActive, not recruiting

Hemoglobin SC DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Hemoglobin SC Disease

#DrugCompanyPhaseTrials

Droxia

Mg Pidolate

BBaylor College of Medicine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemoglobin SC Disease1 trial

Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate

Terminated·—·Phase 2·NCT00040456·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mg Pidolate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mg Pidolate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mg Pidolate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Baylor College of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBaylor College of Medicine

Related News